Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 14/20 | 0.36 |
| ▸ | CCND1 | P24385 | 14/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218319 | 0.87 | CDK4 (0.36) | CDK4CCND1TYMSCA12CA1 | |
| SCHEMBL6216498 | 0.86 | PDE2A (0.39) | CDK4CCND1PDE2ATYMSCA12 | |
| SCHEMBL6217714 | 0.85 | CDK4 (0.41) | CDK4CCND1TYMSCA12CA1 | |
| SCHEMBL6218669 | 0.83 | CDK4 (0.42) | CDK4CCND1TYMSCA12CA1 | |
| SCHEMBL6215863 | 0.81 | CDK4 (0.39) | CDK4CCND1PDE2ATYMSCCNE2 | |
| SCHEMBL6218693 | 0.80 | CDK4 (0.46) | CDK4CCND1TYMSCA12CA1 | |
| SCHEMBL6213926 | 0.80 | CDK4 (0.47) | CDK4CCND1PDE2ATYMSCA12 | |
| SCHEMBL6217402 | 0.79 | CRHR1 (0.31) | — | |
| SCHEMBL6213942 | 0.78 | CDK4 (0.43) | CDK4CCND1TYMSCA12CA1 | |
| SCHEMBL6784008 | 0.72 | CDK4 (0.55) | CDK4CCND1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1176146-B1 | CARBAMOYL TETRAHYDROPYRIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-06-08 | — | — | EP | disclosed |
| US-6894168-B2 | Carbamoyl tetrahydropyridine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-17 | — | — | US | disclosed |
| EP-1449843-A1 | Intermediates for the preparation of carbamoyl tetrahydropyridine derivatives | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-08-25 | — | — | EP | disclosed |
| US-20030191122-A1 | Carbamoyl tetrahydropyridine derivatives | NAKAZATO ATSURO (JP) | 2003-10-09 | — | — | US | disclosed |
| US-6600038-B1 | Intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF. involving Corticotropin Releasing Factor (CRF), such as depression, anxiety, | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| EP-1176146-A1 | CARBAMOYL TETRAHYDROPYRIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191122-A1 | Carbamoyl tetrahydropyridine derivatives | CNR1, CRHR1, CRH | CDK4 2019/4885CCND1 1239/4885PDE2A 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.